Full-Time

Senior Manager Instructional Design and Compliance

Posted on 11/29/2025

Intuitive Surgical

Intuitive Surgical

10,001+ employees

Manufactures robotic surgical systems and services

No salary listed

Sunnyvale, CA, USA

Hybrid

Three days per week on-site at Sunnyvale office.

Category
Training
Requirements
  • 7–10 years of experience in learning instructional design, with significant eLearning development experience
  • A minimum of 4+ years in a leadership role overseeing Instructional Design teams, including responsibility for coaching, performance management, and project delivery
  • 3-5+ years of experience managing corporate compliance training, preferably in the medical device, pharmaceutical, or life sciences industry
  • Experience working in a global, matrixed organization
  • Proven success in global stakeholder engagement and cross-functional collaboration
  • Experience developing training aligned with FDA, ISO, and global regulatory standards
  • Strong project management and communication skills
  • Expertise in adult learning theory, instructional design methodologies, and eLearning tools (e.g., Articulate, Captivate, Veeva Vault)
  • Ability to translate complex regulatory content into engaging, learner-friendly experiences
  • Bachelor’s degree in Training and Education or related field
Responsibilities
  • Lead the design and implementation of a global compliance training strategy aligned with FDA, ISO 13485, EU MDR, and other relevant regulations
  • Develop and maintain a comprehensive compliance training curriculum for all employees, including onboarding, annual refreshers, and role-specific modules
  • Promote a culture of learning, accountability, and training compliance across the organization
  • Establish and enforce instructional design standards and best practices across the enterprise
  • Partner with key stakeholders across Compliance, Legal, Quality, HR, and business units to assess training needs and regulatory requirements
  • Serve as a trusted advisor to senior leaders on compliance training strategy and effectiveness
  • Facilitate regular reviews with stakeholders to ensure training remains relevant, timely, and impactful
  • Oversee the creation of engaging, learner-centered content using adult learning principles and instructional design models (e.g., ADDIE, SAM)
  • Manage the development of eLearning, instructor-led training, microlearning, and performance support tools
  • Ensure content is accessible, inclusive, and aligned with global learning standards
  • Establish an annual compliance training cadence, maintaining a global training calendar and ensure timely delivery and tracking of mandatory training
  • Collaborate with LMS administrators to manage course deployment, reporting, and compliance dashboards
  • Help establish and implement learning evaluation methods and standards appropriate to the learning objectives and outcomes
  • Monitor training effectiveness through metrics, feedback, and audits; drive continuous improvement
  • Lead and mentor a team of instructional designers and training specialists
  • Regularly define and assign stretch goals for the team and individuals, driving for ever-increasing standards, performance, results, and team competencies
  • Set and hold individuals and teams accountable for achieving very high standards of competencies and overall performance
Desired Qualifications
  • Advanced degree or certifications (e.g., RAC, CCEP, CPTD) preferred
  • Familiarity with clinical, manufacturing, and commercial compliance topics
  • High attention to detail, strategic mindset, and a passion for learning and development

Intuitive Surgical designs, manufactures, and sells robotic surgical systems and provides related services and accessories for minimally invasive surgery. The core product helps surgeons perform operations with enhanced precision by guiding robotic arms controlled from a console, allowing procedures to be done through small incisions. Instruments and consumables are used with the systems and are supported by service contracts, creating a recurring revenue stream. Compared to competitors, Intuitive has a large installed base and focuses specifically on robotic-assisted surgery, combining devices, disposable instruments, and ongoing services to support hospitals and surgical centers. Its goal is to improve patient outcomes by enabling safer, less invasive procedures while expanding the use and capabilities of robotic surgery for more procedures and providers.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Simplify Jobs

Simplify's Take

What believers are saying

  • da Vinci 5 updates create software-driven upgrades and workflow monetization.
  • Ion growth expands a second engine beyond soft-tissue robotic surgery.
  • Installed base above 11,000 systems supports durable consumables and service growth.

What critics are saying

  • FDA recalls on da Vinci instruments threaten recurring revenue and surgeon trust.
  • Lower-cost robotic rivals pressure placements, pricing, and hospital contract renewals.
  • MedTech valuation compression can outpace Intuitive's earnings growth for months.

What makes Intuitive Surgical unique

  • Pioneer of robotic-assisted surgery, anchored by da Vinci and Ion platforms.
  • Global leader in minimally invasive care, serving hospitals and surgical centers.
  • Large recurring revenue base from instruments, accessories, and service contracts.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Intuitive Surgical who can refer or advise you

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 7th, 2026
Intuitive Surgical emerges as dark horse in anti-obesity market as surgery outperforms GLP-1 drugs

Intuitive Surgical could emerge as a dark horse in the anti-obesity market as bariatric surgery proves more effective than GLP-1 drugs for long-term weight loss. A recent study of over 50,000 patients found surgery patients lost an average of 58 pounds after two years, compared to just 12 pounds for those using GLP-1 medications. The study also showed surgery delivers more sustainable results. Gastric bypass patients maintain around 52% of their excess weight loss after 10 years, whilst GLP-1 users often regain all lost weight after stopping treatment. Intuitive's da Vinci surgical system offers minimally invasive bariatric surgery options. The company generated $10.1 billion in revenue last year, up from $8.4 billion, with profit margins around 28%. Despite shares falling over 20% this year, the company's position in surgical innovation makes it a compelling long-term investment.

Yahoo Finance
Mar 29th, 2026
Intuitive Surgical shares drop 19% YTD, but analysts see 15% upside potential

Intuitive Surgical has experienced recent share price weakness, declining 3% in one day with negative returns over the past week, month and three months. The stock currently trades at $452.66, down 10.1% over one month and 19.45% year-to-date, though three-year total shareholder returns remain strong at 77.19%. The medical technology company reports annual revenue of $10.1 billion and net income of $2.9 billion, maintaining a dominant position in minimally invasive surgical technology. According to one valuation analysis, Intuitive Surgical's fair value sits at $532.46, suggesting the stock is undervalued by approximately 15% at current levels. The analysis projects 12% annual revenue growth over the next five years, supported by recurring revenues from spare parts and software licences, with profit margins expected to reach 30% from the current 28.6%.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical shares up 23% after Jim Cramer's buy recommendation

Intuitive Surgical shares rose 23% following Jim Cramer's recommendation on CNBC's Squawk on the Street in June 2025, where he urged investors to "just go buy ISRG". The medical robotics company experienced a 27% surge in October after reporting third-quarter earnings that beat analyst estimates. Revenue reached $2.51 billion against expectations of $2.40 billion, whilst adjusted earnings per share hit $2.40 versus the predicted $1.98. However, the stock declined 2.7% in January 2026 after Intuitive Surgical released preliminary fourth-quarter results, citing concerns that Medicaid funding cuts and competing products could slow growth of its robotic surgical systems. Despite the recent setback, shares remain up significantly since Cramer's initial endorsement, though they're down 7.8% over the past year.

Yahoo Finance
Mar 28th, 2026
Intuitive Surgical faces tariff headwinds and rising competition despite 19% revenue growth to $2.87B

Intuitive Surgical faces headwinds from tariffs and increased competition in the robotic-assisted surgery market, yet its fundamentals remain strong. The medical device company reported fourth-quarter revenue growth of 19% to $2.87 billion, whilst adjusted earnings per share rose 14.5% to $2.53. Procedures using its da Vinci surgical system increased 17%, with the installed base growing 12% to 11,106 units. However, the stock trades at 47.6 times forward earnings, compared to the healthcare sector average of 17.1. New competition is emerging, with Medtronic's Hugo system recently cleared and Johnson & Johnson expected to launch its own device soon. Despite these challenges, Intuitive Surgical maintains advantages through switching costs and extensive real-world data, whilst the underpenetrated robotic-assisted surgery market offers long-term growth potential.

Yahoo Finance
Mar 24th, 2026
ISRG maintains 37% operating margins in Q4 despite 95 bps tariff drag

Intuitive Surgical maintained a 37% operating margin in Q4 despite tariffs creating a 95 basis point drag, alongside higher facility costs and unfavourable product mix from newer platforms like da Vinci 5 and Ion. The company offset these pressures through product cost reductions, component savings and manufacturing efficiencies. Procedure growth of 18% in Q4 and recurring revenue now comprising 81% of total revenues provided operating leverage. Management's 2026 gross margin guidance of 67-68% suggests continued stability, even as tariff headwinds are expected to increase to roughly 1.2% of revenues. Meanwhile, Boston Scientific expanded adjusted operating margins by 100 basis points to 28% in 2025, though tariffs will offset favourable product mix in 2026. The company expects 50-75 basis points operating margin expansion in 2026 through scale efficiencies and supply-chain optimisation.

INACTIVE